Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 24 | 25 | 11 | 1 | 3 | 58 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 11 | 34 | 6 | 4 | 3 | 49 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Fallopian tube neoplasms | D005185 | — | — | 18 | 11 | 5 | — | — | 27 |
Ovarian epithelial carcinoma | D000077216 | — | — | 7 | 5 | 2 | — | 2 | 13 |
Sarcoma | D012509 | — | — | 5 | 6 | 1 | — | 1 | 11 |
Lymphoma | D008223 | — | C85.9 | 6 | 6 | 1 | — | — | 9 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 7 | 1 | — | — | 8 |
Endometrioid carcinoma | D018269 | — | — | 5 | 2 | 1 | — | — | 6 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 2 | 4 | — | — | 6 |
Peritoneal neoplasms | D010534 | — | — | 2 | 3 | 1 | — | — | 5 |
Acinar cell carcinoma | D018267 | — | — | 1 | 1 | 1 | — | — | 2 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 9 | 3 | — | — | — | 11 |
Multiple myeloma | D009101 | — | C90.0 | 4 | 10 | — | — | — | 10 |
Plasma cell neoplasms | D054219 | — | — | 2 | 5 | — | — | — | 6 |
Triple negative breast neoplasms | D064726 | — | — | 3 | 2 | — | — | — | 5 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 2 | — | — | — | 4 |
Uterine cervical neoplasms | D002583 | HP_0030159 | — | 1 | 4 | — | — | — | 4 |
Prostatic neoplasms | D011471 | — | C61 | 2 | 2 | — | — | — | 3 |
Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 2 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 1 | — | — | — | 2 |
Esophageal neoplasms | D004938 | — | C15 | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cystadenocarcinoma | D003536 | — | — | 3 | — | — | — | — | 3 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | — | — | — | — | 2 |
Plasma cell leukemia | D007952 | — | C90.1 | 1 | — | — | — | — | 1 |
Brenner tumor | D001948 | — | — | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
Ovarian diseases | D010049 | — | — | 1 | — | — | — | — | 1 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Drug common name | Zoptarelin doxorubicin |
INN | zoptarelin doxorubicin |
Description | Zoptarelin doxorubicin (developmental code names AEZS-108, AN-152) consists of doxorubicin linked to a small peptide agonist to the luteinizing hormone-releasing hormone (LHRH) receptor. It has been developed as a potential treatment for a number of human cancers. The LHRH receptor is aberrantly present on the cell surface of approximately 80% of endometrial and ovarian cancers, 86% of prostate cancers and about 50% of breast cancers. Whereas in normal tissues, expression of this receptor is mainly confined to the pituitary gland, reproductive organs and hematopoietic stem cells. To a lesser extent the LHRH receptor is also found on the surface of bladder, colorectal, and pancreatic cancers, sarcomas, lymphomas, melanomas, and renal cell carcinomas.
|
Classification | Protein |
Drug class | prehormones or hormone-release stimulating peptides; antineoplastic antibiotics (daunorubicin type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 |
PDB | — |
CAS-ID | 139570-93-7 |
RxCUI | — |
ChEMBL ID | CHEMBL3544954 |
ChEBI ID | — |
PubChem CID | 16134409 |
DrugBank | — |
UNII ID | 27844X2J29 (ChemIDplus, GSRS) |